Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a One-Week radiation course be just as good as three weeks for breast cancer?

NCT ID NCT07274800

Disease control Sponsor: Zagazig University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested whether a shorter, more intense course of radiation (1 week) works as well as the standard 3-week course for women with early breast cancer after lumpectomy. Sixty women were split into two groups to compare side effects, cosmetic results, and cancer control over 24 months. The goal is to see if the quicker schedule can be a safe and convenient alternative.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radiotherapy (ultra-hypofractionated vs. hypofractionated)
What this could lead to
If the shorter 1-week schedule proves as safe and effective as the 3-week schedule, it could offer a more convenient treatment option for early breast cancer patients.
What could go wrong
This is a small, single-center study with only 60 participants, so results may not apply to all patients. The shorter schedule might increase side effects or reduce cancer control, but the study aims to compare these outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Nov 2023

Finished

Nov 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria:• Histological diagnosis of breast adenocarcinoma * Prior breast conservative surgery negative resection margins (3 mm) * Pathological stage pT1-pT2, N0-1, pT3-N0, M0 * No macroscopic evidence of distant metastases at diagnosis * Age 18-80 years * Female patients * Normal hematological and biochemical laboratory tests * Written informed consent was obtained from all patients Exclusion Criteria: • Patients underwent mastectomy. * Locally advanced disease pT4, N2,3. * Positive surgical margins * Prior thoracic radiation * Synchronous second primary tumor * Distant metastases * Pregnancy * Presence of a concomitant psychiatric disorder precluding an aware informed consent. * Age \>80 years * Low risk patient meeting all the following criteria (more than or equal 65 years, PT1, grade 1 or 2, +ER, -Her2nu, N0, M0).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast adenocarcinoma breast cancer breast neoplasm invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Zagazig University

    Zagazig, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.